Contents

Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT-ROP)


Main finding: Intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone I but not zone II disease.

 

  • Study name: BEAT-ROP
  • Study type: Randomised controlled Trial
  • Condition: Retinopathy of prematurity

Participants: infants with zone 1 or 2 posterior stage 3+ ROP

 

  • n=150

 

Intervention:

 

Group 1: Intravitreal bevacizumab (0.625mg)
Group 2: laser

Retinopathy of prematurity recurred in 4 infants in the bevacizumab group (6 of 140 eyes [4%]) and 19 infants in the laser-therapy group (32 of 146 eyes [22%], P=0.002).

 

A significant treatment effect was found for zone I retinopathy of prematurity (P=0.003) but not for zone II disease (P=0.27).

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed